Qilu Pharmaceutical Co., Ltd.: Phase 3 study started recruiting, 556 planned (Extensive-stage Small Cell Lung Cancer)
Qilu Pharmaceutical Co., Ltd.: Phase 3 study started recruiting, 556 planned (Extensive-stage Small Cell Lung Cancer). Its enrollment of 556 is top-decile (90th percentile of 8,879 records). Dated 5 days ago, it is inside the fresh trigger window. Score 100/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 556 · 90th percentile of 8,879 ClinicalTrialStartPulse records · 7.0x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer |
| NCT ID | NCT07802821 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Extensive-stage Small Cell Lung Cancer |
| Intervention types | drug |
| Target enrollment | 556 |
| Site countries | China |
| Posted | 2026-09-03 |
| Planned start | 2026-10-27 |
| Event | Started recruiting |
| Event date | 2026-10-27 |
| Last update posted | 2026-10-30 |
| enrollment percentile | 90th of 8,879 (median 80, 7.0x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Qilu Pharmaceutical Co., Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Qilu Pharmaceutical Co. + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-30
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Qilu Pharmaceutical Co., Ltd. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Qilu Pharmaceutical Co., Ltd.'s enrollment: 90th percentile of 8,879 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
100 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 556 participants planned.
What is the ClinicalTrialStartPulse record for Qilu Pharmaceutical Co., Ltd.?
Qilu Pharmaceutical Co., Ltd.'s Phase 3 study (NCT07802821) in Extensive-stage Small Cell Lung Cancer, first posted 2026-09-03: started recruiting (2026-10-27), in an update posted 2026-10-30.
How does Qilu Pharmaceutical Co., Ltd. compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 556 is 7.0x the median of 80 across 8,879 records. It is fresh: dated 5 days ago, inside the window where early outreach matters most. Its Score of 100/100 puts it among the stronger signals in this feed.
Qilu Pharmaceutical Co., Ltd. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | NONUS | 556 | 90th | 2026-10-30 |
| Janssen Research & Development, LLC | US | 539 | 90th | 2026-11-03 |
| Genmab | US | 600 | 91st | 2026-11-03 |
| GlaxoSmithKline | NONUS | 610 | 91st | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Qilu Pharmaceutical Co., Ltd. and peer phase 3 records
Get new ClinicalTrialStartPulse records like Qilu Pharmaceutical Co., Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.